Skip to main content
. 2020 Sep 11;10:1534. doi: 10.3389/fonc.2020.01534

Figure 4.

Figure 4

Prognostic significance of EPAS1 dysregulation in ESCC. (A) The trends of EPAS1-mutated positive patients had shorter survival rates compared to the nonmutated patients. However, the difference did not reach statistical significance level (p = 0.46). (B) Patients with EPAS1 DNA amplification had poorer survival than EPAS1 DNA deletion (p = 0.20). (C) In stage III patients with ESCC, the survival rates of patients having EPAS1 DNA amplification is significantly poor when compared to that of EPAS1 DNA deletion (p = 0.04).